

1 Antimicrobial peptide novicidin synergises with rifampicin, ceftriaxone and ceftazidime against  
2 antibiotic-resistant *Enterobacteriaceae* *in vitro*

3  
4 Odel Soren<sup>a\*</sup>, Karoline Sidelmann Brinch<sup>b</sup>, Dipesh Patel<sup>a</sup>, Yingjun Liu<sup>a</sup>, Alexander Liu<sup>c</sup>, Anthony  
5 Coates<sup>a</sup> and Yanmin Hu<sup>a#</sup>

6  
7 Institute for Infection and Immunity, St George's, University of London, London, United Kingdom<sup>a</sup>.  
8 Novozymes A/S, Bagsvaerd, Denmark<sup>b</sup>. John Radcliffe Hospital, University of Oxford, Oxford,  
9 United Kingdom<sup>c</sup>.

10  
11 #Address correspondence to Yanmin Hu, [ymhu@sgul.ac.uk](mailto:ymhu@sgul.ac.uk)

12 \*Present address: Centre for Biological Sciences, University of Southampton, United Kingdom.

13  
14 Running title: Novicidin Enhancement

15 Key words: *Enterobacteriaceae*, novicidin, antibiotic combination, rifampicin, ceftriaxone,  
16 ceftazidime

17 ABSTRACT

18 The spread of antibiotic resistance amongst Gram-negative bacteria is a serious clinical threat and  
19 infections with these organisms are a leading cause of mortality worldwide. Traditional novel drug  
20 development inevitably leads to the emergence of new resistant strains, rendering the new drugs  
21 ineffective. Therefore, reviving the therapeutic potentials of existing antibiotics represents an  
22 attractive novel strategy. Novicidin, a novel cationic antimicrobial peptide, is effective against Gram-  
23 negative bacteria. Here, we investigated novicidin as a possible antibiotic enhancer. The actions of  
24 novicidin in combination with rifampicin, ceftriaxone and ceftazidime were investigated against 94

25 antibiotic resistant clinical Gram-negative isolates and 7 strains expressing New Delhi metallo- $\beta$ -  
26 lactamase-1 (NDM-1). Using the checkerboard method, novicidin combined with rifampicin showed  
27 synergy with over 70% of the strains, reducing the minimum inhibitory concentrations (MIC)  
28 significantly. The combination of novicidin with ceftriaxone and ceftazidime was synergistic against  
29 89.7% of ceftriaxone-resistant strains and 94.1% of ceftazidime-resistant strains. Synergistic  
30 interactions were confirmed using time kill studies with multiple strains. Furthermore, novicidin  
31 increased the post-antibiotic effect (PAE) when combined with rifampicin or ceftriaxone. Membrane  
32 depolarisation assays revealed that novicidin alters the cytoplasmic membrane potential of Gram-  
33 negative bacteria. *In vitro* toxicology tests showed novicidin to have low haemolytic activity and no  
34 detrimental effect on cell cultures. We demonstrated that novicidin strongly rejuvenates the  
35 therapeutic potencies of ceftriaxone or ceftazidime against resistant Gram-negative bacteria *in vitro*.  
36 In addition, novicidin boosted the activity of rifampicin. This strategy can have major clinical  
37 implications in our fight against antibiotic resistant bacterial infections.

## 38 INTRODUCTION

39 Bacterial infections remain one of the leading causes of death worldwide. The ever escalating problem  
40 of antibiotic resistance leads to the redundancy of many antibiotics, resulting in increased morbidity  
41 and mortality in both developed and developing countries. In particular, the effectiveness of  
42 antimicrobial agents against Gram-negative pathogens, for example *Enterobacteriaceae*, are being  
43 compromised at an alarming rate (1).

44 Bacteria in the *Enterobacteriaceae* family cause an arsenal of serious infections including pneumonia,  
45 wound infections, meningitis, urinary tract infections, intra-abdominal infections (1) and nosocomial  
46 bacteriemia (2). Extended spectrum  $\beta$ -lactamase (ESBL) producing strains now predominate in many  
47 areas, conferring resistance to cephalosporins and remaining sensitive only to carbapenems and the  
48 older, more toxic polymyxin antibiotics such as colistin (3). Furthermore, since 2007, infections with

49 New Delhi metallo- $\beta$ -lactamase 1 (NDM-1) producing ‘superbugs’ have emerged. For these infections  
50 virtually all antibiotics, including carbapenems, are ineffective. Most NDM-1 strains are usually  
51 susceptible only to ‘last line’ drugs like colistin, which exhibits nepro- and neuro-toxicity (4), and the  
52 bacteriostatic glycylycylcline tigecycline (5). The most optimal strategy to overcome resistant infections  
53 is to use novel antimicrobial agents. However, the traditional strategy of antibiotic discovery cannot  
54 maintain pace with the rapid rate of resistance emergence and resistance occurs just a few years after  
55 market release (6). In addition, the discovery of novel antibiotics is costly and arduous which means  
56 producing large numbers of antibiotic classes within a short period of time is extremely challenging  
57 (7-9).

58 Reviving the potency of existing antibiotics by combining them with novel agents is an extremely  
59 desirable strategy to tackle resistance (10). Antimicrobial peptides, in particular those targeting the  
60 bacterial cell envelope, have been shown to synergise with conventional antibiotics (11). The dual  
61 action of weakening of the cell envelope and increasing permeability may allow the intracellular  
62 antibiotic concentration to reach a lethal dose, which is unachievable by the antibiotic alone.  
63 Furthermore, the use of multiple agents in combination may reduce or retard the emergence of  
64 resistance to the individual antimicrobial components (10, 12).

65 It has been suggested that novicidin, a novel 18-residue cationic antimicrobial peptide, acts by  
66 inserting itself into the head group region of the selectively targeted bacterial membrane bilayer. This  
67 subsequently causes membrane perturbation, transient pore formation, and is bactericidal via the  
68 resulting leakage of bacterial cell contents (13-15). Significant antimicrobial effects have been noted  
69 with several Gram-negative organisms, such as *Escherichia coli* and *Salmonella enterica* (15).  
70 Novicidin was developed from ovispirin, which in turn originated from an ovine cathelicidin known  
71 as sheep myeloid antimicrobial peptide (SMAP)-29 (13). This derivation allowed for construction of  
72 a peptide more suitable for use as a therapeutic agent (14).

73 In this study, we aimed to investigate the effects of novicidin in combination with conventional  
74 antibiotics, namely rifampicin and third generation cephalosporins, ceftriaxone and ceftazidime,  
75 against 101 Gram-negative strains including resistant *E. coli* and bacteria in the *Klebsiella*-  
76 *Enterobacter-Serratia* (KES) group. Additionally, investigations were carried out to determine the  
77 mechanism of action, haemolytic activity and cytotoxicity of novicidin.

## 78 MATERIALS AND METHODS

79 **Bacterial strains and growth conditions.** Bacterial strains used were 94 antibiotic resistant Gram-  
80 negative clinical isolates including 61 *E. coli* and 33 isolates in the KES group from St Georges  
81 Hospital, London. In addition, 7 strains harbouring the bla<sub>NDM</sub> plasmid were used: ATCC BAA-2468,  
82 BAA-2469, BAA-2470, BAA-2471, BAA-2472 and BAA-2473 and NCTC 13443. Strain ATCC  
83 BAA-2468 is identified as *Enterobacter cloacae*; ATCC BAA-2469 and BAA-2471 as *E. coli*; and  
84 ATCC BAA-2470, BAA-2472, BAA-2473 and NCTC 13443 as *Klebsiella pneumoniae*. Bacterial  
85 strains were grown in nutrient broth no. 2 (Oxoid, UK) and on tryptone soya agar plates (Oxoid, UK).  
86 Antibiotics used were as follows: rifampicin (Sanofi), ceftriaxone (Stravencon), ceftazidime  
87 (Wockhardt), cefixime (Suprax) and cefotaxime (Reig Jofre). Antibiotics were prepared in water or  
88 the provided solvent to an appropriate concentration. Novicidin was kindly provided by Novozymes  
89 A/S, Denmark.

90 **In vitro susceptibility of novicidin and antibiotics.** The minimum inhibitory concentration (MIC) of  
91 novicidin, rifampicin, ceftriaxone, ceftazidime, cefixime and cefotaxime for the 101 strains were  
92 calculated using the broth micro dilution method. The MIC for each agent was identified as the lowest  
93 concentration required to inhibit bacterial growth. The MIC<sub>50</sub> and MIC<sub>90</sub> were calculated, defined as  
94 the lowest concentration required to inhibit growth in 50% and 90% of the strains respectively.

95 **Chequerboard assays to measure combination effects of novicidin and antibiotics.** The  
96 chequerboard assay method was used for the measurement of combination effects of novicidin with

97 the antibiotics. Combinations of two drugs were prepared in 96 well plates (Fisher Scientific UK)  
98 using drug concentrations starting from two fold higher than their MIC values, then serially diluted in  
99 a two-fold manner. After addition of a log-phase bacterial inoculum of  $1.5 \times 10^5$  colony forming units  
100 (CFU)/ml, plates were incubated at 37°C for 24 hours. and then read using ELx800 absorbance  
101 microplate reader (BioTek). The effects of the combinations were examined by calculating the  
102 fractional inhibitory concentration index (FICI) of each combination as follows: (MIC of drug A,  
103 tested in combination)/(MIC of drug A, tested alone) + (MIC of drug B, tested in combination)/(MIC  
104 of drug B, tested alone). The profile of the combination was defined as synergistic if the FICI was  
105  $\leq 0.5$ , indifferent if the FICI was  $> 0.5$  but  $\leq 4.0$  and antagonistic if the FICI was  $> 4$  (16).

106 **Time kill curves of antibiotics alone and in combination with novicidin.** Two-fold serial drug  
107 dilutions were prepared and added to a 96-well plate alone and in combination, and incubated at 37°C  
108 with a log-phase bacterial inoculum of  $1.5 \times 10^7$  CFU/ml. At 0, 1, 2, 4, 7 and 24 hours of incubation,  
109 viability expressed as CFU/ml was determined by plating 100  $\mu$ l of serial dilutions onto tryptone soya  
110 agar (Oxoid) plates followed by incubation at 37°C for 24 hours. Colonies were counted using  
111 aCOLyte colony counter (Synbiosis) and analysed using the accompanying software. Synergistic  
112 activity was defined as a  $\geq 2$ -log<sub>10</sub> decrease in CFU counts at 24 hours of the combination compared  
113 with the most effective single agent, in addition to  $\geq 2$ -log<sub>10</sub> decrease compared with the 0 hour count.  
114 Indifference was defined as a  $\leq 1$ -log<sub>10</sub> fold change in CFU counts, and antagonism as a  $\geq 2$ -log<sub>10</sub>  
115 increase in CFU at 24 hours, of the combination compared with the most effective single agent (17).

116 **Measurement of bacterial cytoplasmic membrane potential.** The permeability of the bacterial  
117 cytoplasmic membrane after drug treatment was assessed using a fluorescence assay as previously  
118 described (18, 19). Log-phase cultures were washed twice and resuspended in a rejuvenating buffer  
119 (5 mM HEPES, pH 7.2, 20mM glucose) to an optical density of 0.05 at 600 nm. Membrane potential  
120 sensitive dye DiSC3(5) (3'-Dipropylthiadicarbocyanine iodide, Sigma) was added to the resuspended  
121 cells to a final concentration of 0.4  $\mu$ M and incubated until a stable reduction in fluorescence was

122 achieved as a result of DiSC3(5) uptake and cell quenching due to an intact membrane. 100 mM of  
123 KCl was added to equilibrate the K<sup>+</sup> ion concentration intra- and extracellularly. The bacterial cell  
124 suspension was added to a 96-well microtitre plate, followed by addition of drugs in triplicate.  
125 Fluorescence was measured using GloMax-Multi+ microplate reader (Promega) at an excitation  
126 wavelength of 622 nm and an emission wavelength of 670 nm. Any drug induced disruption of the  
127 cytoplasmic membrane resulted in an increase in measurable fluorescence.

128 **Post-Antibiotic Effect (PAE) of antibiotics alone and in combination with novicidin.** Bacteria  
129 were cultured overnight at 37°C in nutrient broth. 1 ml of the culture was transferred to fresh nutrient  
130 broth medium containing single or combinatory drugs. For the single drugs, 2, 5 or 10 fold higher than  
131 MIC values of the drug were utilised. For the combinations, 5 fold higher than the minimal  
132 enhancement concentrations of both drugs were selected according to the checkerboard results. After  
133 1 hour of drug exposure, the cultures were washed three times to remove the antimicrobial agents. The  
134 bacterial cells were resuspended into nutrient broth and grown at 37°C with continuous shaking at 100  
135 rpm. Bacterial viability was determined by CFU counting at 0, 1, 2, 3, 4, 6 and 8 hours. The PAE  
136 was calculated as follows:  $PAE = T - C$ , whereby T= time taken for drug exposed culture to increase  
137 by 1 log CFU counts, and C = time taken for control culture to increase by 1 log CFU counts (20).

138 **Ex vivo haemolysis assay.** A venous blood sample from a male human donor was collected shortly  
139 before testing. 10 µl aliquots of the heparinized blood were added to 0.5 ml of saline solution (0.9%  
140 NaCl) containing different concentrations of novicidin in triplicate. After 1 hour of incubation at  
141 37°C, the mixtures were centrifuged for 5 minutes at 5000 × g to sediment intact cells. The  
142 supernatants were isolated and the absorbance values were measured at a wavelength of 545 nm.  
143 Haemolysis of novicidin was analysed against negative (0% lysis) and positive controls (100% lysis)  
144 to calculate the percentage of haemolysed cells, using the formulae as follows:  $haemolysis = (OD_{test} -$   
145  $OD_{negative\ control}) / (OD_{positive\ control} - OD_{negative\ control}) \times 100$ . An ethic approval (H-D-2007-0055) was  
146 obtained from Danish National Committee on Health Research Ethics for using human blood.

147 **Assessment of cytotoxicity using neutral-red uptake assay.** To assess the effects of cytotoxicity of  
148 novicidin, the L929 mouse fibroblast cell line was utilised. Cells were grown in Eagle's minimum  
149 essential medium (EMEM) with 10% foetal bovine serum (EBS) to 80% confluence. Adherent cells  
150 were harvested and seeded at a concentration  $5 \times 10^5$  cells per well into a 96 well microtitre plate  
151 which was incubated for 24 hours at 37°C. Different concentrations of novicidin were added to the  
152 cells and incubated at 37°C for 24 and 72 hours. Neutral red (25 mg/L) was added post treatment for 3  
153 hours at 37°C and removed by washing the cells twice with phosphate buffered saline containing  
154  $\text{CaCl}_2/\text{MgCl}_2$ . Intracellular neutral red was extracted using neutral red removal solution (50% ethanol,  
155 1% acetic acid and 49% water) for 15 minutes. Neutral red uptake was measured at 540 nm and cell  
156 viability was determined as percentage of the untreated control. Sodium dodecyl sulphate (SDS) was  
157 used as a positive control.

## 158 RESULTS

159 ***In vitro* susceptibility of novicidin and the antibiotics.** The MIC for novicidin, rifampicin,  
160 ceftriaxone, ceftazidime, cefixime and cefotaxime were assessed for the 94 Gram-negative clinical  
161 isolates and 7 NDM-1 strains. As shown in Table 1, the MIC for novicidin for the 101 strains ranged  
162 from 1 to 8 mg/L with an MIC<sub>50</sub> and MIC<sub>90</sub> at 2 and 4 mg/L, respectively. The MIC for rifampicin  
163 varied between 4 to >1024 mg/L. The MIC<sub>50</sub> and MIC<sub>90</sub> were 16 mg/L and 64 mg/L, respectively.  
164 The MIC for ceftriaxone, ceftazidime, cefixime and cefotaxime ranged between 0.03125 and 2048  
165 mg/L. The MIC<sub>50</sub> and MIC<sub>90</sub> were 1024 and 2048 mg/L for ceftriaxone, 128 and 1024 mg/L for  
166 ceftazidime, 256 and 2048 mg/L for cefixime, and 512 and 2048 mg/L for cefotaxime, respectively.

167 **Chequerboard analysis of combination effects.** The combination effects of novicidin combined  
168 with rifampicin, ceftriaxone and ceftazidime were determined using the broth microdilution  
169 chequerboard assay against 94 clinical isolates and 7 NDM-1 strains. The FIC indices for the  
170 combinations are shown in Table 2. The combination of novicidin with rifampicin was shown to have

171 synergistic activity with over 70% of both *E. coli* and isolates in KES group, with FIC indices  
172 between 0.018 and 0.5. In addition, the combination was shown to have synergistic effects with all 7  
173 NDM-1 strains. Novicidin reduced the MIC of rifampicin between 2 to 512-fold, with the majority of  
174 strains exhibiting 4 or 8-fold reductions in MIC values (Supplementary Table 1, 2 and 3). Novicidin  
175 combined with ceftriaxone showed synergy with 57.4% of the *E. coli* strains and 69.7% of isolates in  
176 KES group. The combination of novicidin with ceftazidime presented synergy with 63.9% of the *E.*  
177 *coli* strains and 78.8% of isolates in KES group. The FIC indices for the NDM-1 strains were unable  
178 to be determined as the MIC for ceftriaxone and ceftazidime was higher than the maximum achievable  
179 chequerboard concentration of 2048 mg/L. As revealed in Table 3, synergistic activities were shown  
180 in the majority (89.7%) of the ceftriaxone-resistant strains compared to a minority of the ceftriaxone-  
181 sensitive strains (16.7%). A similar pattern was observed with the novicidin and ceftazidime  
182 combination, whereby synergy was seen in 94.1% of resistant strains compared with 3.8% of sensitive  
183 strains. Novicidin reduced the MIC of ceftriaxone or ceftazidime between 2 to more than 2048-fold  
184 (Supplementary Table 1 and 2).

185 **Time kill assays confirming synergy of novicidin combined with rifampicin, ceftriaxone or**  
186 **ceftazidime.** Time kill assays were performed to examine the activities of novicidin in combination  
187 with rifampicin, ceftriaxone and ceftazidime against 5 strains of *E. coli* and KES group clinical strains  
188 which represented an FIC index <0.5 for each drug combination. The combination of rifampicin and  
189 novicidin was also tested against the 7 NDM-1 strains. A range of different concentrations was tested  
190 according to chequerboard analysis and the most effective and synergistic activities are shown. As  
191 seen in Figure 1, rifampicin at 2 mg/L (Fig. 1A and Fig. 1B) and at 256 mg/L (Fig. 1C and 1D) failed  
192 to reduce the viability of the clinical isolate and the NDM-1 *E. coli*, novicidin at 0.5 or 0.25 mg/L  
193 (Fig. 1A and 1B) and at 4 or 2 mg/L (Fig. 1C and 1D) showed initial kill of the bacteria but regrowth  
194 was seen. However, when rifampicin at 2 mg/L combined with novicidin at 0.5 (Fig. 1A) or 0.25 (Fig.  
195 1B) mg/L, 100% kill of the *E. coli* cells was achieved at 2 and 4 hours post treatment, respectively.



196 Similarly, when rifampicin at 256 mg/L combined with novicidin at 4 (Fig. 1C) or 2 (Fig. 1D) mg/L,  
197 complete kill of the NDM-1 *E. coli* was seen at 4, 7 and 24 hours post treatment, respectively. There  
198 were significant differences in the reduction of CFU counts between the combination of novicidin  
199 with rifampicin and each of the single drug (rifampicin or novicidin) treatment ( $P < 0.0001$ ).

200 Novicidin and ceftriaxone combinations were tested against ceftriaxone resistant *E. coli* and KES  
201 group clinical isolates. As seen in Fig. 1E, 1F, 1G and 1H, ceftriaxone at 2048 mg/L was unable to  
202 reduce the CFU counts of both strains. However, when novicidin was added in the culture at 1 or 0.5  
203 mg/L and 2 or 1 mg/L, the bacterial cells were rapidly killed showing 100% reduction in CFU count at  
204 2 or 4 hours post treatment for the *E. coli* isolate respectively (Fig. 1E and 1F), and at 1 or 2 hours  
205 post treatment for the KES group strain (Fig. 1G and 1H) respectively, demonstrating significant  
206 synergy. There were significant differences in the reduction of CFU counts between combination of  
207 novicidin with ceftriaxone and each of the single drug (ceftriaxone or novicidin) treatment  
208 ( $P < 0.0001$ ). The ability of novicidin enhancement to rifampicin or ceftriaxone was also compared  
209 with another defensin, plectasin which was neither bactericidal on its own nor boosting the activity of  
210 rifampicin (Fig. 1I) or ceftriaxone (Fig. 1J) against Gram-negative bacteria to validate the assay.  
211 Similar patterns of combination activities were observed for the strains tested when novicidin was  
212 combined with ceftazidime (data not shown).

213 **Membrane permeabilising effects of novicidin against *E. coli* and KES group isolates.** The effects  
214 of novicidin at the cytoplasmic bacterial membrane with both *E. coli* and an isolate from the KES  
215 group were investigated with fluorescence assays. Immediately after novicidin exposure, a sharp  
216 concentration dependent increase in fluorescence occurs with the *E. coli* strain (Fig. 2) indicating  
217 disruption of the bacterial membrane which led to the leakage of the fluorescent dye. A similar effect  
218 was observed when novicidin was used to treat the strain in the KES group despite only high  
219 concentrations of novicidin such as 64 and 32 mg/L resulting in an increase in fluorescence (data not  
220 shown).

221 **Post-antibiotic effect of novicidin and novicidin-antibiotic combinations.** The PAE of novicidin,  
222 rifampicin or ceftriaxone singly and in combination was determined; rifampicin was used at 5-fold  
223 higher than the MIC level and ceftriaxone at 10-fold higher than the MIC level. As novicidin was  
224 rapidly bactericidal at 5-fold higher than its MIC concentration, 2-fold higher than MIC level was  
225 used to induce the PAE. Due to their enhanced synergistic activities, the same concentrations for  
226 novicidin and rifampicin or ceftriaxone used singly for PAE induction would completely kill all the  
227 bacterial cells within 1 hour if combined. Therefore, to induce PAE with combination treatment, 5-  
228 fold higher than the minimal enhancement concentrations for novicidin and rifampicin or ceftriazone  
229 were used, chosen from checkerboard results. As shown in Fig. 3A, the PAE of both novicidin and  
230 rifampicin was estimated as 52.8 minutes for the *E. coli* strain. The novicidin and rifampicin  
231 combination doubled the PAE to 121.8 minutes despite substantially lower concentrations being used  
232 ( $P < 0.0001$ ). As shown in Fig. 3B, the PAE of novicidin was 84 minutes and ceftriaxone produced no  
233 PAE. The novicidin and ceftriaxone combination exhibited a prolonged PAE of 117 minutes  
234 ( $P < 0.0001$ ).

235 **Haemolytic effects of novicidin.** Haemolysis of novicidin was tested using human blood. As shown  
236 in Table 4, at the lowest tested novicidin concentration of 125 mg/L, haemolysis occurred at a rate of  
237 4.4% ranging up to 19.9% at the highest tested concentration of 1000 mg/L. The 50% haemolytic  
238 concentration could not be accurately predicated due to the non-linear correlation between novicidin  
239 concentration and haemolysis, however is shown to be  $>1000$  mg/L from the current data.  
240 Extrapolation provides an estimate of between 2500 and 3000 mg/L. 100% haemolysis was seen  
241 when the blood was added into distilled water (Table 4). The experiments were repeated twice with  
242 reproducible results.

243 **Determination of cytotoxicity by neutral-red uptake.** To assess the cytotoxicity of novicidin,  
244 neutral-red uptake was measured after treatment of the murine fibroblasts with different  
245 concentrations of novicidin. As seen in Table 5, cell viability was well conserved and remained

246 between 93% to 99% after 24 hours of novicidin exposure, and 98% to 102% after 72 hours exposure  
247 for all tested concentrations. This indicates low levels of general cytotoxicity even with prolonged  
248 exposure. SDS was used as a positive control: concentrations of 80, 100 and 120 mg/L reduced cell  
249 viability to 80%, 9% and 0% at 24 hours and 55%, 0% and 0% at 72 hours, respectively, confirming  
250 the validity of the assay. The experiments were repeated twice with reproducible results.

## 251 DISCUSSION

252 Novicidin is a newly derived antimicrobial peptide. In this study, we demonstrated for the first time  
253 that novicidin synergised with rifampicin and third generation cephalosporins (ceftriaxone and  
254 ceftazidime) against Gram-negative antibiotic-resistant bacterial strains *in vitro*. The 94 clinical  
255 isolates from the *Enterobacteriaceae* family covered a broad host distribution in the South London  
256 area and the 7 NDM-1 strains represented the most resistant type of Gram-negative bacteria. Most of  
257 the ceftriaxone and ceftazidime resistant bacteria were also resistant to cefotaxime and cefixime  
258 indicating these were ESBL producing strains.

259 Rifampicin is an important component of the combination regimen used for the treatment of  
260 tuberculosis and many Gram-positive bacterial infections (21). Rifampicin is not considered to be  
261 standard treatment for *Enterobacteriaceae* infections, and thus a breakpoint for resistance is not  
262 available. Our results showed that the MIC<sub>50</sub> and MIC<sub>90</sub> for rifampicin were 16 and 32 mg/L,  
263 respectively. Recently, rifampicin has been introduced in combination therapy for the treatment of  
264 infections caused by multi-drug resistant Gram-negative bacteria (22, 23). Our checkerboard analysis  
265 reveals that the combination of novicidin and rifampicin showed synergistic effects with over 70% of  
266 the tested strains with marginally higher effectiveness with the bacterial strains in KES group  
267 compared with *E. coli*. Novicidin was able to revive the activity of rifampicin by reduction of  
268 rifampicin MIC between 2 to 512 fold. The combination was also synergistic with all of the strains  
269 harbouring NDM-1 plasmids. Synergistic activity of novicidin with rifampicin was confirmed using

270 time kill assays, a method allowing for a more dynamic analysis of bactericidal and combinatorial  
271 effects. Time kill assays were performed with multiple strains, repeatedly demonstrating that at  
272 concentrations at which both novicidin and rifampicin were ineffective alone, when combined, rapid  
273 bactericidal activities were seen with 100% elimination of the bacterial cells within a few hours of  
274 drug exposure, which substantially speeded up the treatment duration. Rifampicin alone required  
275 higher concentrations such as 128 mg/L to completely eradicate *E. coli* cells in culture (data not  
276 shown) and this concentration was only able to reduce the CFU counts of a KES group strain by 2  
277 logs (data not shown). However when combined with novicidin at 0.5 or 1 mg/L, rifampicin at  
278 concentrations of just 2 mg/L killed 100% of the bacterial cells at 4 or 2 hours post treatment (Fig. 1A  
279 and 1B). The combination was also able to enhance the activities of rifampicin against the NDM-1  
280 strains (Fig. 1C and 1D), however required high rifampicin concentrations.

281 Novicidin also enhanced the activities of ceftriaxone and ceftazidime. Interestingly, the majority of  
282 synergy was observed with those strains showing resistance to ceftriaxone or ceftazidime. This was  
283 also confirmed with time kill assays tested against multiple strains. Ceftriaxone has a long half-life  
284 and is used to treat septicaemia, pneumonia, meningitis and urinary tract infections. Clinical  
285 pharmacokinetic data revealed that after a single intravenous injection of a standard 2000 mg dose, the  
286 plasma C<sub>max</sub> was approximately 257 mg/L and at 24 hours post administration, the plasma  
287 concentration was approximately 15 mg/L. However, in the urine, the C<sub>max</sub> of ceftriaxone was  
288 approximately 2692 mg/L within 2 hours following 2000 mg intravenously administered (24).  
289 Ceftazidime, like ceftriaxone, has broad spectrum activity and is one of the few agents in this class to  
290 be used clinically against *Pseudomonas* spp. Ceftazidime pharmacokinetic data shows comparative  
291 serum C<sub>max</sub>, as a 1000 mg intravenous dose produced a peak concentration of approximately 140  
292 mg/L. Similarly, much higher concentrations are present in the urine. Up to 6 hours post infusion of a  
293 50 mg/kg dose of ceftazidime, the concentration in collected urine samples ranged from 2370 to 11,  
294 340 mg/L, with approximately 75% of the drug being recovered unchanged (25). Based on this data, it

295 may be argued that novicidin-cephalosporin combinations may not be clinically appropriate for the  
296 treatment of septicaemia as 2048 mg/L appears to be an unattainable serum concentration. However,  
297 pharmacokinetic analysis of novicidin in combination with the antibiotics may give more realistic  
298 estimations of the concentrations required to achieve synergistic and bactericidal effect. Nevertheless,  
299 the extremely high concentrations of both ceftriaxone and ceftazidime in the urine indicate that either  
300 of these in combination with novicidin may be clinically applicable in treating urinary tract infections.

301 The combination of novicidin with rifampicin or ceftriaxone was able to suppress bacterial growth  
302 against our tested bacterial strains after the drugs had been removed. Interestingly, although  
303 ceftriaxone alone was unable to produce a PAE (26), a prolonged PAE was generated in the  
304 combination with novicidin. Therefore, novicidin and the antibiotic combinations, possibly by  
305 prolonging the PAE, are able to reduce the likelihood of resistance development. A longer PAE also  
306 contributes a therapeutic advantage in devising dosing intervals for drug regimens. Generally a longer  
307 PAE enables less frequent drug doses whilst maintaining therapeutic efficacy; this can reduce adverse  
308 effects and increase patient compliance (20).

309 The precise mechanism underlying the antibiotic enhancing activities of novicidin is unclear. Due to  
310 decreased cell envelope permeability and altered efflux-pump systems, Gram-negative bacteria are  
311 intrinsically resistant to many antibiotics, such as rifampicin. Rifampicin inhibits bacterial DNA-  
312 dependant RNA polymerase (23) and its action on bacterial cells is concentration dependent. It has  
313 been shown that compounds which target the cell wall or cell membrane were found to potentiate the  
314 activities of other antibiotics (11, 18, 27, 28). Previous work on artificial membranes showed that low  
315 concentrations of novicidin resulted in transient pore formation and increased concentrations cause  
316 cell membrane disruption (13, 29). It is also suggested that novicidin accumulates on the membrane  
317 surface until a detergent-like disintegration occurred (known as the carpet mechanism) (13).  
318 Consistent with this finding, we showed that novicidin disturbed the cytoplasmic membrane potential  
319 by depolarising the membrane, and even at very low concentrations, significant fluorescence release

320 was observed. It is likely that the enhanced activities of rifampicin by novicidin was due to increased  
321 cell membrane permeability against the Gram-negative bacteria leading to higher intracellular  
322 accumulation of rifampicin (30, 31).

323 Cephalosporins are  $\beta$ -lactam antibiotics and interact with transpeptidases also known as penicillin  
324 binding proteins (PBP) (32), blocking the terminal step in bacterial cell wall biosynthesis (33).  
325 Accordingly, the synergy between novicidin and ceftriaxone or ceftazidime may be attributed to a  
326 'double hit' mechanism: (1) the disruption of the membrane by novicidin, and (2) the inhibition of cell  
327 wall biosynthesis by ceftriaxone or ceftazidime, which may be sufficient in reducing the integrity of  
328 the cell envelope, resulting in cell death. Our checkerboard analysis showed that synergy was more  
329 likely with ceftriaxone or ceftazidime resistant strains, and resistance to such agents is usually due to  
330 the acquisition of plasmids carrying ESBL genes, producing enzymes which hydrolyse the  $\beta$ -lactam  
331 ring of antibiotics. It is unclear how novicidin enhances the activities of these cephalosporins against  
332 resistant strains. We hypothesized that the enhanced antibiotic activities was likely due to the action of  
333 pore formation by novicidin, leading to the elimination of enzymes or plasmids, the resistance  
334 determinants. However, this notion needs to be further tested.

335 The findings from our study demonstrate proof of concept, displaying the potential of peptide-  
336 antibiotic combinations which undoubtedly contribute to important clinical applications. Firstly, our  
337 demonstration of novicidin as a powerful antibiotic enhancer strongly illustrates that other similar  
338 peptides or compounds may potentially be beneficial above and beyond their direct anti-microbial  
339 properties. Secondly, addition of novicidin reduced MICs and improved the rate of bactericidal  
340 activities of antibiotics, therefore highly resistant Gram-negative bacteria which are extremely  
341 difficult to kill can be eliminated from the bacterial culture. Finally, novicidin exhibited a very low  
342 haemolytic activity which was in agreement with those found by Dorosz et al (14). In addition,  
343 novicidin was non-toxic and cell viability was well conserved after treatment with different  
344 concentrations of novicidin. Combination therapy with novicidin shows promise for becoming a novel

345 and much clinically desired therapeutic option to treat “superbug” infections. *In vivo* work is under  
346 way aiming to expose the therapeutic potential of novicidin in the combination regimen to treat  
347 infections caused by antibiotic resistant Gram-negative bacteria.

#### 348 ACKNOWLEDGMENTS

349 This work was funded with support from the European Commission under grant agreement no:  
350 278998, BacAttack. This communication reflects the views only of the author, and the Commission  
351 cannot be held responsible for any use which may be made of the information contained therein.

352 We would like to thank Dr Julie Johnson from St George’s Healthcare NHS Trust for kindly  
353 providing the clinical strains and Novozymes A/S Denmark for providing novicidin.

#### 354 REFERENCES

- 355 1. **Paterson DL.** 2006. Resistance in gram-negative bacteria: *Enterobacteriaceae*. *Am J Infect Control*  
356 **34**:S20-28; discussion S64-73.
- 357 2. **Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, Oh MD, Choe KW.** 2005. Bloodstream infections  
358 caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of  
359 inappropriate initial antimicrobial therapy on outcome. *Antimicrob Agents Chemother* **49**:760-766.
- 360 3. **Pitout JD, Laupland KB.** 2008. Extended-spectrum beta-lactamase-producing *Enterobacteriaceae*: an  
361 emerging public-health concern. *Lancet Infect Dis* **8**:159-166.
- 362 4. **Biswas S, Brunel JM, Dubus JC, Reynaud-Gaubert M, Rolain JM.** 2012. Colistin: an update on the  
363 antibiotic of the 21st century. *Expert Rev Anti Infect* **10**:917-934.
- 364 5. **Nordmann P, Poirel L, Toleman MA, Walsh TR.** 2011. Does broad-spectrum beta-lactam resistance  
365 due to NDM-1 herald the end of the antibiotic era for treatment of infections caused by Gram-  
366 negative bacteria? *J Antimicrob Chemoth* **66**:689-692.
- 367 6. **Gwynn MN, Portnoy A, Rittenhouse SF, Payne DJ.** 2010. Challenges of antibacterial discovery  
368 revisited. *Ann NY Acad Sci* **1213**:5-19.
- 369 7. **Coates AR, Halls G, Hu Y.** 2011. Novel classes of antibiotics or more of the same? *Brit J Pharmacol*  
370 **163**:184-194.
- 371 8. **Thomson CJ, Power E, Ruebsamen-Waigmann H, Labischinski H.** 2004. Antibacterial research and  
372 development in the 21(st) Century--an industry perspective of the challenges. *Curr Opin Microbiol*  
373 **7**:445-450.
- 374 9. **Livermore DM, British Society for Antimicrobial Chemotherapy Working Party on The Urgent Need:  
375 Regenerating Antibacterial Drug D, Development.** 2011. Discovery research: the scientific challenge  
376 of finding new antibiotics. *J Antimicrob Chemoth* **66**:1941-1944.
- 377 10. **Kalan L, Wright GD.** 2011. Antibiotic adjuvants: multicomponent anti-infective strategies. *Expert Rev*  
378 *Mol Med* **13**:e5.
- 379 11. **Hu Y, Liu A, Vaudrey J, Vaiciunaite B, Moigboi C, McTavish SM, Kearns A, Coates A.** 2015.  
380 Combinations of beta-Lactam or Aminoglycoside Antibiotics with Plectasin Are Synergistic against  
381 Methicillin-Sensitive and Methicillin-Resistant *Staphylococcus aureus*. *PLoS ONE* **10**:e0117664.



- 382 12. **Soothill G, Hu Y, Coates A.** 2013. Can we prevent antimicrobial resistance by using antimicrobials  
383 better? *Pathogens* **2**:422-435.
- 384 13. **Nielsen SB, Otzen DE.** 2010. Impact of the antimicrobial peptide Novicidin on membrane structure  
385 and integrity. *J Colloid Interf Sci* **345**:248-256.
- 386 14. **Dorosz J, Gofman Y, Kolusheva S, Otzen D, Ben-Tal N, Nielsen NC, Jelinek R.** 2010. Membrane  
387 interactions of novicidin, a novel antimicrobial peptide: phosphatidylglycerol promotes bilayer  
388 insertion. *J Phys Chem B* **114**:11053-11060.
- 389 15. **Balakrishnan VS, Vad BS, Otzen DE.** 2013. Novicidin's membrane permeabilizing activity is driven by  
390 membrane partitioning but not by helicity: a biophysical study of the impact of lipid charge and  
391 cholesterol. *Biochim Biophys Acta* **1834**:996-1002.
- 392 16. **Odds FC.** 2003. Synergy, antagonism, and what the chequerboard puts between them. *J Antimicrob*  
393 *Chemoth* **52**:1.
- 394 17. **White RL, Burgess DS, Manduru M, Bosso JA.** 1996. Comparison of three different in vitro methods of  
395 detecting synergy: time-kill, checkerboard, and E test. *Antimicrob Agents Chemother* **40**:1914-1918.
- 396 18. **Hu Y, Coates AR.** 2012. Enhancement by novel anti-methicillin-resistant *Staphylococcus aureus*  
397 compound HT61 of the activity of neomycin, gentamicin, mupirocin and chlorhexidine: in vitro and in  
398 vivo studies. *J Antimicrob Chemoth.* **68**:374-84.
- 399 19. **Wu M, Hancock RE.** 1999. Interaction of the cyclic antimicrobial cationic peptide bactenecin with the  
400 outer and cytoplasmic membrane. *J Biol Chem* **274**:29-35.
- 401 20. **Spivey JM.** 1992. The postantibiotic effect. *Clin Pharm* **11**:865-875.
- 402 21. **Rodriguez-Pardo D, Pigrau C, Corona PS, Almirante B.** 2015. An update on surgical and antimicrobial  
403 therapy for acute periprosthetic joint infection: new challenges for the present and the future. *Expert*  
404 *Rev Anti-Infe* **13**:249-265.
- 405 22. **Nastro M, Rodriguez CH, Monge R, Zintgraff J, Neira L, Rebollo M, Vay C, Famiglietti A.** 2014. Activity  
406 of the colistin-rifampicin combination against colistin-resistant, carbapenemase-producing Gram-  
407 negative bacteria. *J Chemother* **26**:211-216.
- 408 23. **Drapeau CM, Grilli E, Petrosillo N.** 2010. Rifampicin combined regimens for gram-negative infections:  
409 data from the literature. *Int J Antimicrob Ag* **35**:39-44.
- 410 24. **Patel IH, Chen S, Parsonnet M, Hackman MR, Brooks MA, Konikoff J, Kaplan SA.** 1981.  
411 Pharmacokinetics of ceftriaxone in humans. *Antimicrob Agents Chemother* **20**:634-641.
- 412 25. **Leeder JS, Spino M, Tesoro AM, MacLeod SM.** 1983. High-pressure liquid chromatographic analysis of  
413 ceftazidime in serum and urine. *J Antimicrob Chemoth* **24**:720-724.
- 414 26. **Burgess DS.** 2005. Use of pharmacokinetics and pharmacodynamics to optimize antimicrobial  
415 treatment of *Pseudomonas aeruginosa* infections. *Clin Infect Dis* **40 Suppl 2**:S99-104.
- 416 27. **Giacometti A, Cirioni O, Del Prete MS, Barchiesi F, Fortuna M, Drenaggi D, Scalise G.** 2000. In vitro  
417 activities of membrane-active peptides alone and in combination with clinically used antimicrobial  
418 agents against *Stenotrophomonas maltophilia*. *Antimicrob Agents Chemother* **44**:1716-1719.
- 419 28. **Anantharaman A, Rizvi MS, Sahal D.** 2010. Synergy with rifampin and kanamycin enhances potency,  
420 kill kinetics, and selectivity of de novo-designed antimicrobial peptides. *Antimicrob Agents Chemother*  
421 **54**:1693-1699.
- 422 29. **Bertelsen K, Dorosz J, Hansen SK, Nielsen NC, Vosegaard T.** 2012. Mechanisms of peptide-induced  
423 pore formation in lipid bilayers investigated by oriented 31P solid-state NMR spectroscopy. *PLoS ONE*  
424 **7**:e47745.
- 425 30. **Pages JM, Sandrine AF, Mahamoud A, Bolla JM, Davin-Regli A, Chevalier J, Garnotel E.** 2010. Efflux  
426 pumps of gram-negative bacteria, a new target for new molecules. *Curr Top Med Chem* **10**:1848-  
427 1857.
- 428 31. **Zechini B, Versace I.** 2009. Inhibitors of multidrug resistant efflux systems in bacteria. *Recent Pat Anti*  
429 *infect Drug Discov* **4**:37-50.
- 430 32. **Barbas JA, Diaz J, Rodriguez-Tebar A, Vazquez D.** 1986. Specific location of penicillin-binding proteins  
431 within the cell envelope of *Escherichia coli*. *J Bacteriol* **165**:269-275.



- 432 33. **Kosowska-Shick K, McGhee PL, Appelbaum PC.** 2010. Affinity of ceftaroline and other beta-lactams  
433 for penicillin-binding proteins from *Staphylococcus aureus* and *Streptococcus pneumoniae*. *Antimicrob*  
434 *Agents Chemother* **54**:1670-1677.
- 435
- 436
- 437

Table 1. MIC values for novicidin and antibiotics used in this study.











	MIC range (mg/L)	MIC50 (mg/L)	MIC90 (mg/L)
Novicidin	1 - 8	2	4
Rifampicin	4 - >1024	16	32
Ceftriaxone	0.03125 - >2048	1024	2048
Cefixime	0.03125 - >2048	256	2048
Ceftazidime	0.03125 - >2048	128	1024
Cefotaxime	0.03125 - >2048	512	2048

Table 2. Combination activity of novicidin with rifampicin, ceftriaxone and ceftazidime against the 101 Gram-negative *Enterobacteriaceae* strains


Strains	Combination Activity	FICI	Total no. (%) of strains with activity when novicidin combined with		
			Rifampicin	Ceftriaxone	Ceftazidime
<i>E. coli</i>	Synergy	≤0.5	43 (70.5%)	35 (57.4%)	39 (63.9%)
	Indifferent	>0.5 <4	18 (29.5%)	26 (42.6%)	22 (36.1%)
	Antagonism	≥4	0	0	0
Isolates in KES group	Synergy	≤0.5	28 (84.8%)	23 (69.7%)	26 (78.8%)
	Indifferent	>0.5 <4	5 (15.2%)	10 (30.3%)	7 (21.2%)
	Antagonism	≥4	0	0	0
NDM-1 strains	Synergy	≤0.5	7 (100%)	-	-
	Indifferent	>0.5 <4	0	-	-
	Antagonism	≥4	0	-	-

Table 3. Combination activity of novicidin with ceftriaxone and ceftazidime against the 94 Gram-negative clinical isolates

Strains (total no.)	Total no. (%) of strains with activity of novicidin combined with ceftriaxone and ceftazidime		
	Synergy	Indifferent	Antagonism
	FICI $\leq 0.5$	FICI $>0.5 < 4$	FICI $\geq 4$
Ceftriaxone resistant strains [58]	52 (89.7%)	6 (10.3%)	0
Ceftriaxone sensitive strains [36]	6 (16.7%)	30 (83.3%)	0
Ceftazidime resistant strains [68]	64 (94.1%)	4 (5.9%)	0
Ceftazidime sensitive strains [26]	1 (3.8%)	25 (96.2%)	0





1 FIG 1 Time-kill analysis showing the effects of novicidin in combination with rifampicin,  
2 ceftriaxone and ceftazidime against antibiotic resistant *E. coli* and strains. The peptide and  
3 antibiotics alone or each combined with novicidin were added to the bacterial cultures and  
4 CFU counts were carried out at different time points. Combination of rifampicin at 2 mg/L  
5 and novicidin at 1 mg/L (A) or 0.5 mg/L (B) against a clinical isolate of *E. coli*. Combination  
6 of rifampicin at 256 mg/L and novicidin at 4 mg/L (C) or 2 mg/L (D) against a NDM-1 *E.*  
7 *coli*. Combination of ceftriaxone at 2048 mg/L and novicidin at 1 mg/L (E) or 0.5 mg/L (F)  
8 against a clinical isolate of *E. coli*. Combination of ceftriaxone at 2048 mg/L and novicidin at  
9 2 mg/L (G) or 1 mg/L (H) against a clinical isolate of the KES group. Negative controls  
10 were included as (I) combination of plectasin at 32 mg/L with rifampicin at 256 mg/L against  
11 a DN1-1 *E. coli* and (J) combination of plectasin at 32 mg/L with ceftriaxone at 2048 mg/L  
12 against a clinical isolate of the KES group. These results shown are mean with standard  
13 deviation (SD) of two independent experiments.



1 FIG 2 Determination of cytoplasmic membrane potential by novicidin against a clinical  
2 isolate of *E. coli*. Log phase *E. coli* culture was incubated with DiSC3(5) to a final  
3 concentration of 0.4  $\mu$ M until no more quenching was detected, which was followed by  
4 addition of 0.1 M KCl. Novicidin were incubated with the cultures at different  
5 concentrations. The changes in fluorescence were monitored at various time points. The data  
6 was mean with SD of two independent experiments.

7





1 FIG 3 Induction of PAE of rifampicin (A) and ceftriaxone (B) by novicidin against a clinical  
2 isolate of *E. coli*. Concentrations used for single drug PAE induction are rifampicin 80 mg/L,  
3 novicidin 2 mg/L and ceftriaxone 1024 mg/L. For combination PAE induction, rifampicin  
4 was 20 mg/L and novicidin was 0.625 mg/L; ceftriaxone was 640 mg/L and novicidin was  
5 0.625 mg/L. The data was mean with SD of two independent experiments.  
6

Table 4. The haemolytic effects of novicidin at different concentrations

Novicidin concentration (mg/L)	Haemolysis (%)
125	4.4
250	7.7
500	13.2
750	13.3
1000	19.9
Negative control*	0
Positive control**	100

\*blood was mixed with saline solution. \*\*blood was mixed with distilled water

Table 5. Cell viability following treatment with novicidin assessed via neutral red uptake

	Concentrations (mg/L)	Viability (%)	
		24 hours	72 hours
Novicidin	0	100	100
	25	95	102
	50	93	102
	100	99	98
	200	99	101
SDS	80	80	55
	100	9	0
	120	0	0